Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
Case Reports in Gastroenterology · 13.06.2022 · 16 (2) · 388-393
DOI: 10.1159/000525012 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Gastroenterology, online erschienen am 13.06.2022. Verfasst von Aaron G Issac und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McGovern Medical School, Houston, Texas, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Encorafenib, a BRAF kinase inhibitor, in combination with binimetinib, a selective MEK inhibitor have known gastrointestinal adverse events; however, adverse colitis events have not been well studied. We report a case series of 4 patients with melanoma who developed inflammatory colitis after BRAF and MEK inhibition with encorafenib and binimetinib, respectively. In the setting of immune checkpoint inhibitor use, BRAF and MEK inhibitors can cause significant inflammatory colitis with endoscopic patterns of predominant right colon ulcerations. It can lead to significant morbidity and frequent interruption of cancer treatment. Early recognition and prompt intervention are critical to improving patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, McGovern Medical School, Houston, Texas, USA.
- Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Gastroenterology, Hepatology, & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zitieren
APA
Issac, A. G., Szafron, D., Wei, D., McQuade, J. L., & Wang, Y. (2022). Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy. Case Reports in Gastroenterology, 16(2), 388-393. https://doi.org/10.1159/000525012
Vancouver
Issac AG, Szafron D, Wei D, McQuade JL, Wang Y. Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy. Case Reports in Gastroenterology. 2022;16(2):388-393. doi:10.1159/000525012
BibTeX
@article{Issac2022,
author = {Issac, Aaron G and Szafron, David and Wei, Dongguang and McQuade, Jennifer L and Wang, Yinghong},
title = {Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy},
journal = {Case Reports in Gastroenterology},
year = {2022},
volume = {16},
number = {2},
pages = {388--393},
doi = {10.1159/000525012}
}
EUVIMED